Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug developers switch gears to inhibit STING

Nature Biotechnology volume 37, pages 199–201 (2019)Cite this article

Several biotechs are exploring STING inhibitors as a means to control innate immunity and inflammation.

Eli Lilly is the latest large pharma company to set its sights on cGAS–STING, the mechanism used by cells to sense DNA danger signals and trigger the fast-acting innate immune response. In December, Lilly entered a pact with Aduro Biotech to develop cGAS–STING inhibitors as anti-inflammatory agents. The deal involves a modest $12 million up front but a hefty $620 million per product in potential development and commercial milestones. It reflects growing industry interest in the therapeutic possibilities of shutting down a signal cascade that leads to immune activation. Such efforts complement existing industry programs that seek to instead upregulate STING as a means to potentiate checkpoint inhibitor treatments in cancer (Box 1).

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Authors and Affiliations

  1. Dublin, Ireland

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Drug developers switch gears to inhibit STING. Nat Biotechnol 37, 199–201 (2019). https://doi.org/10.1038/s41587-019-0060-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0060-z

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing